[1] FRIAS J P, BONORA E, NEVÁREZ RUIZ L, et al. Efficacy and safety of dulaglutide 3.0 and 4.5 mg in patients aged younger than 65 and 65 years or older: Post hoc analysis of the AWARD-11 trial [J]. Diabetes Obes Metab, 2021, 23(10): 2279-2288.
[2] BODE B W, BRETT J, FALAHATI A, et al. Comparison of the efficacy and tolerability profile of liraglutide, a once-daily human GLP-1 analog, in patients with type 2 diabetes ≥65 and <65 years of age: a pooled analysis from phase III studies [J]. Am J Geriatr Pharmacother, 2011, 9(6): 423-433.
[3] MENEILLY G S, ROY-DUVAL C, ALAWI H, et al. Lixisenatide therapy in older patients with type 2 diabetes inadequately controlled on their current antidiabetic treatment: The GetGoal-O Randomized Trial [J]. Diabetes Care, 2017, 40(4): 485-493.
[4] DRUCKER D J. The cardiovascular biology of glucagon-like peptide-1 [J]. Cell Metab, 2016, 24(1): 15-30.
[5] GERSTEIN H C, COLHOUN H M, DAGENAIS G R, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial [J]. Lancet, 2019, 394(10193): 121-130.
[6] KRISTENSEN S L, RORTH R, JHUND P S, et al.Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials [J]. Lancet Diabetes Endocrinol, 2019, 7(10): 776-785.
[7] GILBERT M P, BAIN S C, FRANEK E, et al. Effect of liraglutide on cardiovascular outcomes in elderly patients: a post hoc analysis of a randomized controlled trial [J]. Ann Intern Med, 2019, 170(6): 423-426.
[8] WILDING J P H, BATTERHAM R L, CALANNA S, et al.Once-weekly semaglutide in adults with overweight or obesity [J]. N Engl J Med, 2021, 384(11): 989-1002.
[9] RIDDLE M C, GERSTEIN H C, XAVIER D, et al.Efficacy and safety of dulaglutide in older patients: a post hoc analysis of the REWIND trial [J]. J Clin Endocrinol Metab, 2021, 106(5): 1345-1351.
[10] 中国老年2型糖尿病防治临床指南编写组, 中国老年医学学会老年内分泌代谢分会, 中国老年保健医学研究会老年内分泌与代谢分会, 等. 中国老年2型糖尿病防治临床指南(2022年版)[J]. 中华内科杂志, 2022, 61(1):12-50.
[11] GOUGH S C, BODE B, WOO V, et al.Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes [J]. Lancet Diabetes Endocrinol, 2014, 2(11): 885-893.
[12] ARODA V R, ROSENSTOCK J, WYSHAM C, et al. Efficacy and safety of LixiLan, a titratable fixed-ratio combination of insulin glargine plus Lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: The LixiLan-L Randomized Trial [J]. Diabetes Care, 2016, 39(11): 1972-1980.
[13] LINGVAY I, HANDELSMAN Y, LINJAWI S, et al.Efficacy and safety of Ideglira in older patients with type 2 diabetes [J]. Endocr Pract, 2019, 25(2): 144-155.
[14] HANDELSMAN Y, CHOVANES C, DEX T, et al. Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes [J]. J diabetes Complications, 2019, 33(3): 236-242. |
